Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
What it found
No result yet.
What it measured
Main measures
Expanded Disability Status Scale (EDSS)
Baseline
Disability progressionStandardized Mini-Mental Test
Baseline
Thinking and memorySymbol Digit Modalities Test
Baseline
Thinking and memoryMultiple Sclerosis Impact Scale (MSIS-29)
Baseline
Quality of life (reported by participants)Glial Fibrillary Acidic Protein (GFAP)
Baseline
Blood or spinal fluid markersNeurofilament Light Chain (NfL)
Baseline
Blood or spinal fluid markersVascular Endothelial Growth Factor (VEGF)
Baseline
Blood or spinal fluid markers
Who could take part
Progressive MS · 18 to 60
Inclusion Criteria: * Confirmed diagnosis of MS * Progressive type MS * Voluntary participation * Age between 18-60 years * Cooperative * EDSS score ≥ 5.5 Exclusion Criteria: * Presence of another neurological disorder * Change in medication within the last 3 months * Relapse within the last 3 months
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Loading reviews and guidelines…
History
Started
Apr 2026
Main results due
Apr 2026
Finished
May 2026
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error